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The inter-cellular propagation of tau aggregates in several neurodegenerative diseases
involves, in part, recurring cycles of extracellular tau uptake, initiation of endogenous
tau aggregation, and extracellular release of at least part of this protein complex.
However, human brain tau extracts from diverse tauopathies exhibit variant or “strain”
specificity in inducing inter-cellular propagation in both cell and animal models. It is
unclear if these distinctive properties are affected by disease-specific differences in
aggregated tau conformation and structure. We have used a combined structural
and cell biological approach to study if two frontotemporal dementia (FTD)-associated
pathologic mutations, V337M and N279K, affect the aggregation, conformation and
cellular internalization of the tau four-repeat domain (K18) fragment. In both heparin-
induced and native-state aggregation experiments, each FTD variant formed soluble
and fibrillar aggregates with remarkable morphological and immunological distinctions
from the wild type (WT) aggregates. Exogenously applied oligomers of the FTD
tau-K18 variants (V337M and N279K) were significantly more efficiently taken up
by SH-SY5Y neuroblastoma cells than WT tau-K18, suggesting mutation-induced
changes in cellular internalization. However, shared internalization mechanisms were
observed: endocytosed oligomers were distributed in the cytoplasm and nucleus of
SH-SY5Y cells and the neurites and soma of human induced pluripotent stem cell-
derived neurons, where they co-localized with endogenous tau and the nuclear protein
nucleolin. Altogether, evidence of conformational and aggregation differences between
WT and disease-mutated tau K18 is demonstrated, which may explain their distinct
cellular internalization potencies. These findings may account for critical aspects of the
molecular pathogenesis of tauopathies involving WT and mutated tau.
Keywords: tau protein, Alzheimer’s disease, frontotemporal dementia, MAPT mutations, oligomer, nuclear tau,
cellular internalization, induced pluripotent stem cell-derived neurons
Abbreviations: AD, Alzheimer’s disease; ANOVA, analysis of variance; CBD, corticobasal degeneration; DPBS, Dulbecco’s
phosphate buffered saline; EDTA, ethylenediaminetetraacetic acid; FTD, frontotemporal dementia; hiPSC-derived neurons,
human induced pluripotent stem cell-derived cortical neurons; LMW, low molecular weight; MT, microtubule; NFT,
neurofibrillary tangle; PHF, paired helical filaments; PIPES, piperazine-N,N′-bis(2-ethanesulfonic acid); SF, straight filament;
TCEP, tris(2-carboxyethyl)phosphine; TEM, transmission electron microscopy; WT, wild type.
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INTRODUCTION
Tauopathies are characterized by the intracellular accumulation
of NFTs composed of aggregated misfolded tau (Arriagada
et al., 1992; Spillantini and Goedert, 2013). NFTs can be
formed when tau proteins lose affinity for MTs and bind to
themselves, forming insoluble aggregates that can subsequently
develop into NFTs (Goedert, 2016). Although monomeric tau –
the physiological form of the protein – is natively unfolded,
it becomes progressively enriched in β-sheets through initial
aggregation into soluble conformers and then into PHFs
and NFTs (Barghorn et al., 2004; von Bergen et al., 2005).
Although growing evidence indicates that tau dysfunction can
cause neurodegeneration, the mechanisms involved are not well
understood (Guo and Lee, 2014; Walsh and Selkoe, 2016).
Many recent studies have shown that the typical temporal and
spatial accumulation of tau inclusions in specific brain regions
in AD and other tauopathies may be due to the propagation of
aggregated tau between synaptically connected neurons (Frost
et al., 2009; Guo and Lee, 2014; Usenovic et al., 2015). This
inter-neuronal propagation of abnormal tau, often referred to as
“spread,” is understood to initiate the structural and functional
differences observed in affected brain regions (Boluda et al., 2015;
Usenovic et al., 2015). As a predominantly cytosolic protein,
the spread of tau is expected to involve repeated cycles of the
following steps: (i) secretion of tau, either in aggregated or soluble
forms, from donor neurons; (ii) uptake of extracellular tau into
specific neighboring neurons; (iii) induction of endogenous tau
aggregation in the recipient neurons; and (iv) the secretion of
at least part of this internalized tau-endogenous tau protein
complex (Clavaguera et al., 2009; Frost et al., 2009; Guo and
Lee, 2011; Lasagna-Reeves et al., 2012a; Michel et al., 2014).
Nonetheless, the molecular mechanism governing this process
is poorly understood (Walsh and Selkoe, 2016). As such,
an improved understanding of the pathways involved in these
diseases could lead to the development of new therapies.
The efficiency of the inter-cellular propagation of pathological
tau appears to be influenced by the conformations of both
the seed (internalized) and the seeded (recipient endogenous)
proteins (Goedert et al., 2014; Sanders et al., 2014; Wegmann
et al., 2015; Alonso et al., 2016; Kaufman et al., 2016). This
has therefore led to the tau strain hypothesis, which proposes
that different aggregated tau conformers (distinct strains) will
have distinct pathology-initiating capacities because they interact
with endogenous tau differently (Sanders et al., 2014; Gerson
et al., 2016). This hypothesis is supported by several studies
(Clavaguera et al., 2013; Sanders et al., 2014; Boluda et al.,
2015; Kaufman et al., 2016; Narasimhan et al., 2017; Strang
et al., 2017). For example, intracerebral introduction of human
tauopathy brain isolates into brains of the non-filament-forming
ALZ17 mice led to distinctions in the induction of tau inclusions,
dependent on the source of homogenate (Clavaguera et al.,
2013). Inclusions formed after injecting isolates from human
AD, progressive supranuclear palsy, argyrophilic grain disease,
CBD or tangle-only dementia propagated between neighboring
brain regions. Conversely, propagation was not observed for
aggregates formed in the case of Pick’s disease. Importantly, these
results were similar to those recorded after seeding WT mice
with the same isolates, suggesting that the genetic background
of the animals did not influence the outcome (Clavaguera et al.,
2013). Similarly, intracerebral introduction of brain extracts
from human CBD and AD cases into young tangle-forming
PS19 mice brains resulted in the formation and propagation
of tau inclusions and neuronal loss that appeared specific to
selected cell types (Boluda et al., 2015). Extracts from CBD
patients led to tau inclusions limited to oligodendrocytes of the
fimbria and white matter around the injection site, while tau
aggregates formed after introducing AD extracts were found in
neuronal perikaya without obvious oligodendrocyte participation
(Boluda et al., 2015). These results suggest that tau isolates
from different sources can exhibit distinctions in their ability
to induce tau inclusion formation in the recipient cell type,
which may be due to conformational differences between the
endogenous tau and the initiating tau seeds. Recently, both cell-
type specificity and differential endogenous tau recruitment have
been implicated as determinants of inter-cellular propagation
of human tauopathy brain extracts (Narasimhan et al., 2017).
Furthermore, recombinant full-length and truncated forms of
tau, such as the four-repeat K18 region comprising residues
244–372 of full-length tau 441 (Figure 1), have been shown to
initiate propagation by inducing endogenous tau aggregation
(Guo and Lee, 2011; Iba et al., 2013; Michel et al., 2014; Falcon
et al., 2015; Usenovic et al., 2015). This seeding capacity may
be due to conformational similarities between some forms of
recombinant tau applied as seeds and the endogenous tau,
because these recombinant forms can take on endogenous tau
conformation in some cell models (Falcon et al., 2015).
Whilst there is mounting data supporting the inter-cellular
propagation of aggregated recombinant WT tau, we know little
about FTD (Bodea et al., 2016). Many familial FTD cases are
characterized by single point mutations in the MAPT gene,
which encodes the tau protein. Specific FTD-associated MAPT
mutations have been shown to alter the aggregation, β-sheet
propensity, isoform ratio and MT binding properties of the WT
tau (Hong et al., 1998; Barghorn et al., 2000; von Bergen et al.,
2001; Combs and Gamblin, 2012; Kaniyappan et al., 2017). It
is, however, unclear if aggregated tau proteins from FTD with
MAPT mutations are conformationally distinct from WT tau,
and if they have different cellular internalization behavior and co-
localization dynamics with endogenous tau. Strang et al. (2017)
recently demonstrated that the ability of exogenous WT tau K18
fibrils to induce aggregation in cells over-expressing tau carrying
different FTD mutations is uniquely dependent on the specific
mutation and its surrounding amino acid sequences. However,
several questions remain, such as what structural features
determine these distinct activities? Do the conformation and
aggregation characteristics of tau variants influence their cellular
internalization and endogenous tau interaction? Furthermore,
it has been shown that the N279K variant of the tau 250–300
fragment localizes to the nucleus more efficiently that the WT
when overexpressed in a mammalian cell line (Ritter et al.,
2018). It is yet to be shown if exogenously applied aggregates
of this and other FTD variants of tau can enter recipient
cells and localize to the nucleus, in a process suggestive of
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FIGURE 1 | Schematic illustration of the N279K and V337M mutations in tau. The K18 fragment used in this study was constructed based on the full-length human
brain tau isoform (2N4R; htau40). The N279K mutation is located in the alternatively spliced second repeat region (R2), specifically within the hexapeptide motif at
the start of R2 (PHF6∗; gray). The V337M mutation can be found at the start of the fourth repeat domain, and falls within the third hexapeptide motif (PHF6∗∗;
second gray region).
cell-to-cell propagation. Answering these questions is critical
to understanding the mechanisms by which AD and non-AD
tauopathies develop, and will help to establish if selectivity is
required in drug development for treating tauopathies.
In this study, we investigated the in vitro conformation and
aggregation of tau K18-WT and two FTD variants, namely
V337M and N279K. The N279K mutation is a part of the PHF6∗
hexapeptide motif (275VQIINK280) but the V337M mutation
is located in the PHF6∗∗ hexapeptide motif (337VEVKSE342)
(Li and Lee, 2006; Grüning et al., 2014). Since these motifs
critically regulate tau aggregation and seeding behavior, amino
acid mutations were hypothesized to alter these processes (von
Bergen et al., 2000, 2001; Li and Lee, 2006; Grüning et al., 2014;
Falcon et al., 2015). In addition, the N279K and V337M are
located in the second and the fourth MT binding repeat regions,
respectively (Figure 1). Thus, the characterization of these
mutations should offer new understanding into the consequences
of disease-related alterations in alternatively- and constitutively
spliced domains. The mutations also have distinct pathological
consequences in human brains (Hong et al., 1998), suggesting
differential effects on tau aggregation and structure.
We have shown that the structural morphology and immuno-
reactivity of K18-WT aggregation products were distinctively
altered in the presence of each mutation. Furthermore,
internalization of exogenous structurally defined oligomers into
SH-SY5Y cells was significantly increased in the presence of
each FTD mutation. However, the sub-cellular localization and
endogenous tau co-localization patterns were similar between the
three protein variants, both in SH-SY5Y cells and differentiated
human induced pluripotent stem cell (hiPSC)-derived neurons.
This may suggest shared mechanisms of cellular uptake, but
differences in the efficiency of uptake, between WT tau K18 and
its V337M and N279K FTD variants. Together, the results give
new insights into the structural and functional dynamics of WT
and FTD tau. We hypothesize that the distinct conformation
and aggregation behaviors of the tau K18 variants may influence
their inter-cellular propagation characteristics. These findings
may help to explain important aspects of similarities and
heterogeneity in tauopathies involving WT and mutated tau.
MATERIALS AND METHODS
Materials
Heparin (#H3393), SH-SY5Y cells (#94030304), sodium chloride
(#S/3160/60), sodium phosphate dibasic (#S9763-500 G),
sodium phosphate monobasic dihydrate (#04269-1 KG), Triton
X-100 (#X100-500 ML), Tween (#P9416-100 ML), F12 Ham
(#51651C), L-Glutamine (#G7513), fetal bovine serum (#F2442)
and antibiotic antimycotic acid (#A5955) were purchased
from Sigma Aldrich, St. Louis, Missouri, United States.
X1 Amersham Protran 0.45 µm electrochemiluminescence
nitrocellulose membrane (#15259794) and Amersham
electrochemiluminescence system (#RPN2108) were obtained
from GE Healthcare, Buckinghamshire, United Kingdom. EDTA
(#D/0700/53) was bought from Fisher Scientific, Loughborough,
United Kingdom. PIPES (#A16090) was bought from Alfa Aesar,
Heysham, United Kingdom, whilst DMSO (cell culture-grade;
#P60-36720100) was from PAN-Biotech GmbH, Aidenbach,
Germany. CL-XPosure Film (#34089) and ProLong Gold
antifade mounting medium (#P36934) were purchased from
Thermo Fisher Scientific, Rockford, Illinois, United States.
CellMask
R©
Deep Red plasma membrane stain (#C10046),
Hoechst 33342 (#H21492) and Alexa Fluor
R©
488 C5-maleimide
(#A10254) were bought from Molecular Probes, Eugene, Oregon,
United States. Lactate dehydrogenase (LDH) cytotoxicity assay
kit (#88954) was obtained from Pierce Biotechnology, Rockford,
Illinois, United States. TCEP (#A2233,0001) was procured
from Applichem GmbH, Damstadt, Germany. SynaptoRedTM
C2 (FM4-64; #70021) was obtained from Biotium Hayward,
California, United States. CellViewTM dishes (#627975) were
procured from Greiner Bio-One, Kremsmünster, Austria.
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TABLE 1 | Antibodies used in this study.
Host
Antibody Epitope species Vendor Dilution
Primary antibodies
Polyclonal rabbit anti-
human tau (#A0024)
The MT binding
repeat of tau
Rabbit Dako 1:1000
T22 oligomeric tau
(#ABN454)
Tau MT binding
domain
Rabbit Merck 1:1000
HT7 anti-human tau
(#MN1000)
Amino acid sequence
159PPGQK163 of full
length human tau
2N4R
Mouse Thermo
Scientific
1:100
Alexa Fluor
R©
647-conjugated
anti-nucleolin
(#ab198580)
Human nucleolin Mouse Abcam 1:500
Secondary antibodies
Goat anti-rabbit IgG
(#31460)
– Goat Thermo Fisher
Scientific
1:1000
Alexa Fluor
R©
594-conjugated
AffiniPure goat
anti-mouse
– Goat Jackson
ImmunoResearch
1:100
Formvar/carbon-coated 300-mesh copper grids (#S162)
and mica (#G250-3) were purchased from Agar Scientific,
Stansted, Essex, United Kingdom. Neural precursor cells
(#ax0016), Axol neural maintenance medium kit (#ax0031),
and Surebond reagent (#ax0041) were purchased from Axol
Bioscience, Little Chesterford, Cambridge, United Kingdom.
Marvel dried skimmed milk was obtained from Premier
Foods Company, United Kingdom. Antibodies used have been
described in Table 1.
Site Directed Mutagenesis, Protein
Expression and Purification
Detailed description of the construction of the pProEx-
HTa-Myc-K18 plasmid, and sequence-verified site-directed
mutagenesis to create plasmid variants encoding the V337M
and N279K mutations has been provided previously (Karikari
et al., 2017). To prevent potential adverse functional effects of
maleimide labeling, the native cysteines located in the central core
of the MT binding region were each changed to alanine (C291A,
C322A) and a new cysteine placed outside the central core of
this region (I260C). These cysteine modifications were achieved
by site-directed mutagenesis as described (Karikari et al., 2017).
Several studies have used this approach, understood not to impact
tau aggregation behavior, to study the biochemical properties
and internalization of extracellular tau (Kumar et al., 2014;
Michel et al., 2014; Shammas et al., 2015). The same cysteine-
modified proteins were used in all experiments. Plasmids
encoding N-terminal 6xHis-c-Myc K18-WT, K18-V337M and
K18-N279K were expressed in BL21 (DE3)∗pRosetta Escherichia
coli, purified with immobilized metal affinity chromatography
and quantified with the Bicinchoninic acid assay as described
previously (Karikari et al., 2017).
Filament Assembly and Structural
Characterization Using Negative-Stain
Transmission Electron Microscopy (TEM)
K18-WT or its variants (38.5 µM) mixed with 125 µM heparin
were incubated at 37◦C without agitation for 4 or 45 days.
Sodium phosphate buffer pH 7.4 was the diluent buffer used
in all biochemical experiments unless otherwise indicated. All
incubation was performed using an Eppendorf Mastercycler
thermocycler, and aliquots removed for TEM. Five microliters
of the indicated proteins were pipetted onto glow-discharged
formvar/carbon-coated 300-mesh grids for 2 min, and filter paper
strips used to remove unbound samples. Thereafter, 5 µl of 2%
uranyl acetate was added for 2 min, and the excess removed
as previously before imaging. Quantitative analyses of filament
lengths and widths were performed using Image J.
Dot Blot Analysis of Protein
Conformation
Protein variants at 55 µM were incubated at 37◦C to promote
aggregation. Aliquots removed at the given times were snap-
frozen and stored at −80◦C until needed. After diluting samples
1:2, 2 µl of the diluted samples were spotted onto 0.45-µm
nitrocellulose membrane, air-dried, blocked for 30 min at room
temperature with 10% non-fat milk in phosphate buffered saline
(PBS), and washed five times using 10% Tris buffered saline-
0.05% Tween. The membrane was incubated for 2 h in anti-tau
#A0024 or T22, washed as previously, and incubated with anti-
rabbit immunoglobulin G (Table 1) for a further 2 h. Each
antibody was diluted 1:1000. The membrane was then washed
five times, developed using electrochemiluminescence reagents
(Amersham), imaged and analyzed as previously described
(Karikari et al., 2017).
Preparation and Characterization of
Labeled Oligomers
Proteins were treated with five times excess of TCEP for 1 h,
and then treated with 4× Alexa Fluor 488-C5-maleimide in the
presence of 1× BRB buffer (1 mM KCl, 80 mM PIPES, and 1 mM
EDTA pH 6.8). Free fluorophore was dialyzed out against dialysis
buffer (50 mM Tris HCl pH 7.5, 100 mM NaCl) in Slide-A-Lyzer
MINI Dialysis Device (5 K MWCO; Thermo Fisher Scientific)
with punctured buffer reservoirs placed in containers that can
hold 2 L of dialysis buffer. The buffer was changed every 2 h
with a total of five buffer replacements. Labeling was confirmed
using non-denaturing sodium dodecyl sulfate-polyacrylamide
gel electrophoresis followed by ultraviolet light exposure. The
efficiency of labeling was routinely estimated using Beer’s law and
the molar extinction coefficient of 72,000/cm/M for Alexa Fluor
488-C5-maleimide.
SH-SY5Y Cell Culture
SH-SY5Y cells were cultured on 1:1 minimal essential medium/
F12 Ham medium supplemented with 1% L-Glutamine, 15% fetal
bovine serum, and 1% antibiotic antimycotic acid (10,000 units
penicillin, 10 mg streptomycin and 25 µg amphotericin B). All
experiments were performed using cells between passages two
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and ten. Cells were grown at a density of 200,000 cells/ml in
CellViewTM dishes, 10 µM labeled tau oligomers added to the
medium, and incubated for 24 h at 37◦C, 5% CO2. After removing
the used medium, the cells were washed with warm PBS and fresh
medium with 2 µM Hoechst and 1:1000 dilution of CellMask
Deep Red added before imaging.
hiPSC-Derived Neuronal Culture
Neural precursors – from cord blood CD34+ cells of a newborn
female – that had been cultured for 21 days from iPSCs to neural
precursor cells were bought from Axol Bioscience. Grade 12-well
tissue culture plates (Corning, New York, United States) or plates
containing plasma-cleaned and ethanol-sterilized 13 mm glass
coverslips (Menzer, Thermo Fisher Scientific) were each pre-
coated with 250 µl/cm2 ReadySet reagent (Axol Bioscience) and
kept at 37◦C, 5% CO2 for 45 min. The plates were then rinsed
4× with double-distilled water. Thereafter, Surebond reagent
(Axol Bioscience) diluted in DPBS was added to the plates at
200 µl/cm2 and kept at 37◦C, 5% CO2 for at least 1 h. Cells
were seeded on plasma-cleaned 13 mm glass coverslips at 25,000
cells/cm2 final density and stored at 37◦C, 5% CO2. The media
was changed every other day for 14–16 days using the Axol
Neural Maintenance Medium kit (#ax0031, Axol Bioscience).
Phase contrast microscopy images taken periodically with the
EVOS XL Core Imaging System (Life Technologies) and the
expression of neuron-specific markers (data not shown) were
used to monitor neuronal differentiation. Tau K18 oligomers
diluted to 5 µM in neural maintenance medium were applied to
cultured neurons and kept at 37◦C, 5% CO2 for 24 h, after which
the used medium was carefully removed and the neurons washed
with DPBS before the addition of fresh medium.
Immunocytochemistry
SH-SY5Y cells: the appropriate antibodies or dye were applied
to the cells as described above and images taken with confocal
microscopy without fixing. In internalization analysis, fresh
media containing FM4-64 (2 µM) and Hoechst was added to
cells after PBS wash as explained above. The cells were imaged
after 30 min incubation at 37◦C and 5% CO2. Nucleolin co-
localization was investigated by adding a 500× dilution of an
Alexa Fluor-647-labeled anti-human nucleolin (Table 1) in tau-
free medium to tau oligomer-treated cells after PBS wash as
described above. Cells were imaged after 2 h incubation at 37◦C
and 5% CO2. Cells were imaged without fixing.
hiPSC-derived neurons: Neurons were fixed with 4%
paraformaldehyde for 30 min, twice washed with DPBS and
then cleaned with permeabilizing solution (0.2% Triton in
DPBS). Thereafter, the fixed neurons were stored in blocking
buffer (DPBS containing 0.2% Triton and 2% BSA) for 1 h.
Subsequently the cells were incubated with primary antibody and
Hoechst for 1 h at 37◦C and 5% CO2. The fixed neurons were
washed thrice, each for 5 min, with blocking buffer to remove
unbound primary antibody and then incubated for 1 h with
secondary antibody diluted in blocking buffer. After incubation
with the secondary antibody, the wash steps were repeated.
The prepared coverslips were rinsed with distilled water and
slide-mounted with ProLong Gold antifade mounting medium.
Slides were incubated in the dark for at least 24 h before imaging.
Details of antibodies used are available in Table 1.
Confocal Microscopy
An LSM 710 (Leica) equipped with an C-Apochromat 63×/1.20
W Korr M27 objective lens was used to image SH-SY5Y cells.
hiPSC-derived cortical neurons were imaged with the 63×
objective of a Leica STP 6000 microscope. Images were analyzed
with Image J. Internalization data are expressed as integrated
density (area × mean fluorescent intensity). Identical imaging
settings were used for each set of experiments (at least n = 3).
LDH Assay
The Pierce LDH cytotoxicity assay kit was used. SH-SY5Y cells
were seeded at 20,000 cells/well in Falcon 96-well plates and
the indicated oligomer concentrations added. Controls included
spontaneous cytotoxicity (cells + 10 µl sterile water), media
only (no cells) and maximum control (membrane lysed with a
manufacturer-supplied reagent). Cells were incubated for 72 h
at 37◦C 5% CO2. After incubation, lysis buffer was added
to the maximum control wells and the plate incubated for
a further 45 min. An aliquot (50 µl) of the sample mix in
each well was transferred to a new 96-well plate and 50 µl
reaction mix from the kit added to each well before incubation
in the dark for 30 min. Stop solution (50 µl) was added and
absorbance measured at 490 and 680 nm. Background readings
at 680 nm were subtracted from corresponding 490 nm readings
and LDH release (cytotoxicity) for each condition calculated
by dividing that condition’s LDH activity value by the value
for the maximum LDH activity control, and subtracting the
spontaneous LDH activity value from both the numerator and
the denominator.
Statistics
Statistical analysis was done using Prism 6 (GraphPad Inc.,
CA, United States) at 95% confidence interval. The D’Agostino
and Pearson test was used to test the datasets for normality.
Whenever appropriate, parametric analysis was performed using
one-way ANOVA with Tukey’s post hoc test. Conversely, non-
parametric datasets were analyzed using Kruskal–Wallis test
with Dunn’s post hoc test. Data are shown as mean ± standard
error of the mean.
RESULTS
The K18 fragment consists of residues critical for tau aggregation
and conformation, including the hexapeptide motifs at the
beginning of repeat domains two (275VQIINK280), three
(306VQIVYK311), and four (337VEVKSE342) (Figure 1). These
motifs control aggregation by modulating tau-tau interactions
that lead to conformational changes from random coil to cross
β-sheet structures (von Bergen et al., 2000, 2005; Li and Lee, 2006;
Grüning et al., 2014). Moreover, protomers comprising residues
306–378 form the core of tau filaments, with their differential
packing mechanisms determining the type of aggregates formed
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(Fitzpatrick et al., 2017). Furthermore, the protein’s aggregation-
seeding competence, partly responsible for its inter-cellular
propagation, is held in the repeat region and its fragments
consisting of specific motifs (Guo and Lee, 2011; Michel et al.,
2014; Stöhr et al., 2017). As the repeat region contains residues
that control tau aggregation, conformation and propagation, the
K18 fragment was used to study potential effects of specific FTD
mutations on these properties.
Familial FTD Mutations Alter the
Ultra-Structure of Tau K18 Aggregates
Negative-stain TEM was used to study effects of the N279K and
V337M mutations on tau K18 aggregation. Each sample was
incubated with heparin at 37◦C for four days (96 h) before TEM
analysis. After this aggregation period, K18-WT mostly formed
PHFs and, to a lesser degree, SFs. Both phenotypes of K18-WT
have been reported previously (Barghorn and Mandelkow, 2002).
The PHFs had different degrees of twisting, which increased
up to ∼45◦ (Figure 2A and Supplementary Figure S1A).
Unlike the PHFs, the SFs had no obvious helical structures
(Figure 2Aiii). Tau K18-V337M aggregates had two types of
phenotypes: large amorphous aggregates (Figure 2B main image)
and short filamentous aggregates (Figure 2B inset). On the other
hand, K18-N279K formed thick bundles of filaments of various
width and length (Figure 2C). Supplementary Figure S1 is
an extension of Figure 2, showing representative images from
n = 3 independent experiments using different batches of purified
proteins which further demonstrate the variety of aggregates
formed by each tau K18 variant.
Filament length was significantly different when comparing
all three proteins (p < 0.0001, Kruskal–Wallis test; mean
lengths = 510.8± 42.3 nm, 106.6± 15.4 nm, and 534.8± 42.9 nm
for WT, V337M, and N279K K18, respectively). Note that for
K18-V337M, only the fibrils, but not the irregular amorphous
structures, were analyzed. Filaments from both K18-WT and
K18-N279K were significantly longer than those formed by
K18-V337M (p < 0.0001, Kruskal–Wallis test with Dunn’s
post hoc test; Figure 2D). Filament length between K18-WT
and K18-N279K were not significantly different to each other
(p > 0.9999, Kruskal–Wallis test with Dunn’s post hoc test).
However, the three protein variants had significantly different
filament widths (p < 0.0001, Kruskal–Wallis test; mean filament
width = 27.9 ± 4.2 nm for K18-WT, 21.1 ± 0.8 nm for
FIGURE 2 | Structural changes in tau K18 filaments formed in the presence of the V337M and N279K FTD mutations after 4 days of incubation. (A) Representative
electron micrographs of K18-WT, showing PHFs and SFs. (B) Representative electron micrographs of K18-V337M, which formed amorphous aggregates and short
filaments (examples shown in the main figure and inset, respectively). (C) Representative electron micrographs of K18-N279K, showing bundled filaments of different
shapes and widths. Scale bar = 100 nm for all images. Extended examples of the tau aggregates shown here can be found in Supplementary Figure S1. (D,E)
Box plots of filament lengths and widths, respectively for the tau K18 variants. The plots show the results of a total of 73, 112, and 47 analyzed fibrillar structures for
K18-WT, K18-V337M, and K18-N279K, respectively across n = 3 independent experiments using different batches of purified proteins. Kruskal–Wallis test followed
by Dunn’s post hoc test; ∗∗∗∗ = p < 0.0001, ns, not significant.
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K18-V337M, and 53.0 ± 8.3 nm for K18-N279K), with K18-
WT and K18-V337M filaments being similar (p = 0.6698,
Kruskal–Wallis test with Dunn’s post hoc test; Figure 2E).
K18-N279K filaments were significantly wider than those
of K18-WT and K18-V337M (p < 0.0001 in both cases,
Kruskal–Wallis test with Dunn’s post hoc test; Figure 2E).
Together, the morphology and structural properties of K18-
WT aggregates significantly changed in the presence of the
FTD mutations, causing a shift from PHFs and SFs to
unstructured, amorphous aggregates and shorter but wider
filaments for K18-V337M, with K18-N279K aggregating into
bundled filaments of similar length to those of K18-WT but of
increased width.
Phenotypes of Tau K18 Aggregates Do
Not Change With Further Incubation
As aggregation and fracture are thought to modulate the
aggregation of tau K18 (Meyer et al., 2016). incubation
times were increased to ascertain if the structural properties
identified after 4 days would be maintained following prolonged
incubation. Because aggregate conformation is partly determined
by soluble tau recruitment onto template conformers (Margittai
and Langen, 2004; Guo and Lee, 2014), it is conceivable
that multiple cycles of aggregation and fracture may favor
the growth of minor conformers which would otherwise
be undetected in shorter experiments (Meyer et al., 2014,
2016). The previously described TEM experimental setup
was employed to image samples obtained from extended
incubation periods (45 days). The aggregates formed had
the same morphological phenotypes as those seen after
4 days for all protein variants (Figure 3), indicating that the
conformation of K18-WT aggregates is changed by the N279K
and V337M mutations, and that these conformations persist
during extended incubation.
FTD Mutations Alter Immuno-Reactivity
and Aggregation Products of Tau K18
The unique aggregation and structural properties of the
FTD variants of K18 (Figures 2–3) are consistent with the
hypothesis that they alter K18-WT conformation. In these
experiments, heparin was added to accelerate the aggregation
and filament formation process. However, the transient nature
of heparin-treated tau aggregation can preclude the detection of
important conformational changes. The tau proteins’ propensity
to self-aggregate into filaments in the heparin-free state
and the conformations they adopt during this process were
therefore, studied.
Reactivity to specific antibodies (total tau A0024 (K9JA) and
T22 oligomer conformation-preferring) was used to test for any
further indication of distinct conformations, since proteinopathic
protein variants with different conformations can lead have
differential immuno-reactivity profiles (Hatami et al., 2017).
Incubation time was extended to 314 h without agitation to allow
PHF formation. Incipient immuno-reactivity was analyzed by
dot blotting (Figure 4 and Supplementary Figure S2). K18-WT
had the strongest immuno-reactivity to the total tau antibody
FIGURE 3 | The distinct structural phenotypes of tau K18 aggregates
observed in the presence of the FTD mutations do not change with extended
aggregation reactions. (A) K18-WT formed PHFs and SFs, similar to those
recorded in the 4 days assay in Figure 2A. (B) K18-V337M formed
amorphous aggregates in addition to short filaments, similar to those
observed in the 4 days aggregation assay in Figure 2B. (C) K18-N279K
formed thick filament bundles whose structural features shares major
similarities with those in Figure 2C. Scale bar = 100 nm for all images. Three
independent experiments each performed with a different batch of purified
protein.
A0024 at 0 h but this decreased over time (Figures 4A,B, upper
panels). Similar immuno-reactivity, to A0024, of K18-N279K
to that of K18-WT was observed, with the highest intensities
recorded at early time points. However, K18-V337M had the
lowest immuno-reactivity at each time point: the intensity at 0 h,
the strongest recorded, was similar to the lowest intensity for
K18-WT at 314 h (Figures 4A,B).
To gain insight into possible differences in oligomer
conformation, reactivity to the oligomer-preferring T22 antibody
was analyzed. Similar to its reactivity to A0024, K18-WT had its
highest T22 immuno-reactivity at 0 h, which dropped sharply
from 168 h onward (Figures 4A,B; lower panels). The reactivity
of K18-V337M was low at all time points except at 24 h.
K18-N279K had the least intensity to T22 at each time point
(Figures 4A,B; lower panels and Supplementary Figure S2).
This result implies that each protein variant folds differently with
distinct epitope exposure during aggregation.
Dominant Aggregate Conformers of the
Tau K18 Variants Are Unaffected by
Seeded Aggregation
Mutations in tau K18 can cause preferential amplification of
specific aggregate conformers (Meyer et al., 2014). However,
it is unknown if the dominant tau K18 conformers are affected
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FIGURE 4 | The FTD mutations change the immuno-reactivity of tau K18. (A) Dot blots of K18-WT and its FTD variants aggregating in heparin-free conditions
probed with two different tau antibodies; total tau (A0024 from Dako) and the oligomer-preferring T22. The dot blot data shown here were from identical
experiments, with uncropped images shown in Supplementary Figure S2. (B) Semi-quantification of dot blot intensity using heat maps.
by seeded aggregation. We therefore, studied if the mutation-
induced dominant conformations of the tau K18 variants are
affected by the addition of aggregated seeds from different
tau K18 variants. Using the same experimental setup as in
Figure 2, we seeded monomers of tau K18 WT, V337M, and
N279K each with 10% volume of 4 days preformed aggregates
from each protein variant. Negative-stain TEM imaging showed
that seeded reactions (Supplementary Figures S3B–D) resulted
in aggregate structures with the same phenotypes as those in
seed-free experiments (Supplementary Figure S3A, same as
in Figure 2) irrespective of the seed identity. These results
suggest that the conformations of the tau K18 aggregates are
not only be distinct but may also be incompatible, and that the
majority species preferentially aggregate even when seeded with
other conformers.
Preparation and Characterization of
Fluorescent K18 Oligomers for
Functional Studies
Distinct structures of tau strains are thought to explain
their divergent functional effects (Clavaguera et al., 2013;
Boluda et al., 2015; Falcon et al., 2015; Narasimhan
et al., 2017). We therefore, sought to take advantage of
the conformational and aggregation differences of the
tau K18 variants to investigate their possible influences
on the cellular internalization of exogenously applied
oligomers. To achieve this, Alexa Fluor-488-C5-maleimide-
labeled oligomers were first prepared as detailed in section
“Materials and Methods” and elsewhere (Karikari et al.,
2019) before being used in in vitro cell culture assays.
These stable oligomers were granular and non-fibrillar
(Supplementary Figure S4).
FTD Mutations Enhance Tau K18
Oligomer Internalization in
SH-SY5Y Cells
Increasing evidence suggests that the cellular internalization of
tau oligomers is an initial trigger of tau pathology (Usenovic
et al., 2015; Kolarova et al., 2017). It is, however, not known
if FTD with tau mutations are characterized by the same
or similar mechanism. To address this, fluorescently labeled
oligomers of K18-WT, K18-V337M, and K18-N279K were
applied exogenously to SH-SY5Y cells and their internalization
dynamics investigated.
All three tau protein variants were internalized by SH-SY5Y
cells (Supplementary Figures S5–S8). To account for both
diffused and punctate phenotypes, we used integrated density
(mean intensity x area occupied) to quantify internalized tau
in experiments, where equal numbers of cells were seeded
and treated with equimolar concentrations of each protein
oligomers. The internalization data for each tau K18 variant
was analyzed by normalizing the mean integrated density
from representative images to the overall mean of the WT
(Figure 5). Internalization was significantly different between
the three protein variants (one-way ANOVA, p = 0.0007,
F statistic = 10.08). The Tukey’s multiple comparison post hoc
test showed that internalization was significantly higher for both
K18-V337M (p = 0.0122) and K18-N279K (p = 0.0006) against
K18-WT but not significantly different between K18-V337M and
K18-N279K (p = 0.4524, Figure 5).
Exogenous Tau K18 Oligomers Are
Internalized by Endocytosis
Previous reports have suggested that K18-WT is internalized
by endocytosis (Guo and Lee, 2011; Michel et al., 2014).
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FIGURE 5 | Distinct internalization of K18-WT, K18-V337M, and K18-N279K
oligomers in SH-SY5Y neuroblastoma cells. Plot of tau K18 oligomer
internalization in SH-SY5Y cells. For each condition, the same number of cells
was treated with 10 µM of each protein oligomers as explained in section
“Materials and Methods.” The graph shows % mean integrated density data
normalized to WT. Internalization was significantly different between the tau
K18 protein variants (p = 0.0007); significantly higher for both K18-V337M and
K18-N279K against K18-WT (p = 0.0122 and p = 0.0006, respectively), using
one-way ANOVA followed by Tukey’s post hoc test. The dotted line shows the
mean internalization data for the WT (100%) to which the rest of the data was
compared. ∗Signs refer to significance levels as used in the figure.
However, the internalization mechanism of the FTD variants
used in this study was not known. The endocytic marker
FM4-64
R©
(SynaptoRed) was used to stain SH-SY5Y cells
during internalization, allowing a preliminary assessment of
the localization of the internalized tau. Similar to K18-WT,
internalized K18-V337M and K18-N279K oligomers co-localized
with FM4-64, suggesting endocytic-dependent internalization
(Figures 6A–C). As a control, incubating SH-SY5Y cells
seeded with K18 oligomers at 4◦C instead of 37◦C blocked
internalization (Supplementary Figure S9) as shown before
for tau K18 and full-length tau 441 (Michel et al., 2014). We
next tested if oligomer internalization in a more physiologically
relevant cell model, hiPSC-derived neurons, also occurred by
endocytosis. Tau taken up by neurons were ostensibly found in
both neurites and soma, where they appeared to co-localize with
FM4-64 in both compartments (Figures 6D–F). Together, these
data suggest that tau K18 oligomers can be internalized by SH-
SY5Y cells and hiPSC neurons at least partly through endocytosis.
Internalized Tau K18 Oligomers
Co-localize With Endogenous Tau and
the Nuclear Protein Nucleolin
The ability of internalized tau oligomers to interact with
endogenous tau is a critical step in the inter-cellular propagation
of tau (Lasagna-Reeves et al., 2012a; Michel et al., 2014; Usenovic
et al., 2015). It is, however, unknown if tau variants of different
conformations will interact with endogenous tau differently upon
internalization. Internalized K18 oligomers were observed to co-
localize with endogenous tau in hiPSC-derived neurons bearing
the 159PPGQK163 epitope (HT7 antibody). All three tau K18
variants co-localized with endogenous tau, occurring both in the
neurites and the soma (Figure 7), suggestive of an interaction of
internalized tau with endogenous tau.
The nuclear localization of both endogenous tau and tau
overexpressed from genetic constructs has been reported in both
the human and mouse brains (Rady et al., 1995; Liu and Götz,
2013) and cell culture models (Lu et al., 2014; Ritter et al.,
2018). Nuclear tau staining is often predominantly apparent in
the nucleolus, with tau signals co-localized with those of the
nucleolar protein nucleolin (Sjöberg et al., 2006), although more
diffuse nuclear staining for endogenous tau has been reported
in response to cell stress (Sultan et al., 2011). In SH-SY5Y cells,
the internalized tau was not generally detected in the nucleus.
Although some association with nucleolin was observed, this was
expected to result from the redistribution of the nucleolin protein
during the different phases of the cell cycle in these dividing cells
(data not shown). Cytoplasmic accumulation of internalized tau,
as has been previously demonstrated, was recorded for both cell
types. However, in contrast to the SH-SY5Y cells, tau-nucleolin
co-localization was observed in hiPSC-derived neurons with
nucleolar inclusion of internalized tau for both mutant and WT
tau-K18 (Figure 8).
Internalized Tau K18 Oligomers Do Not
Induce LDH-Dependent Cytotoxicity in
SH-SY5Y Cells
Several studies have shown that internalized tau oligomers impair
cell viability and/or induce cell death (Lasagna-Reeves et al.,
2010; Guerrero-Muñoz et al., 2015) but others have reported the
opposite (Kumar et al., 2014; Kaniyappan et al., 2017). However,
the cytotoxicity potential of tau FTD variants is unknown.
SH-SY5Y cells were therefore, treated with the respective
oligomers and cytotoxicity studied by measuring LDH release.
No significant differences in viability were observed between
increasing concentrations of WT or mutant K18 oligomers
(Figure 9), suggesting that the oligomers did not induce LDH-
dependent cytotoxicity over 72 h.
DISCUSSION
Tau has important functions in the pathogenesis of AD and
FTD (Ghetti et al., 2015; Wang and Mandelkow, 2016; Guo
et al., 2017). Whilst several theories have been proposed toward
understanding disease mechanisms, recent studies have pointed
to possible involvement of an inter-neuronal transmission
mechanism. Although this hypothesis has strong evidential
support (Mohamed et al., 2013; Guo and Lee, 2014; Hu et al.,
2016), it remains to be shown why tau isolates from different
post-mortem tauopathy brains have distinct internalization
and transmission capabilities. In this study, an integrated
structural and cell biological approach was used to understand
potential links between protein aggregation, conformation and
cellular internalization. It was hypothesized that specific disease-
associated MAPT mutations implicated in familial FTD will
alter the structural features (conformation and aggregation) and
cellular internalization of WT tau K18. It has been demonstrated
that the N279K and V337M FTD-linked mutations do alter
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FIGURE 6 | Extracellular tau K18 oligomers are taken up by endocytosis, with the internalized soluble aggregates localizing to the neurites and soma of
hiPSC-derived neurons. Panels (A–C), respectively, show co-localization of oligomers of K18-WT, K18-V337M, and K18-N279K internalized by SH-SY5Y cells with
the FM4-64 endocytosis marker. (D–F) Internalized exogenous oligomers of K18-WT, K18-V337M, and K18-N279K, respectively, co-localized with the FM4-64
endocytosis marker in hiPSC-derived neurons. Whilst some of the internalized oligomers of all three protein variants were found in the neurites (arrowheads), others
appeared to be present in the soma (arrows). Scale bar = 10 µm for all images.
tau K18 aggregation and conformation. Moreover, the mutants
had enhanced cellular internalization, yet all protein variants
were internalized by endocytosis and had shared the same sub-
cellular accumulation patterns. These data suggest that structural
distinctions between tau variants may influence their cellular
internalization properties, with potential implications for the
molecular pathogenesis of tauopathies.
Previous studies of the V337M and N279K mutations did
not identify any discernible effects on tau aggregation propensity
(Barghorn et al., 2000; Combs and Gamblin, 2012). This may
have been due to the use of thioflavin fluorescent reporter
assays to quantify aggregation (Barghorn et al., 2000; Combs
and Gamblin, 2012). Although commonly used to detect cross
β-sheet-dependent aggregation (Lindberg et al., 2015), a major
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FIGURE 7 | Internalized tau K18 oligomers in hiPSC-derived neurons co-localize with endogenous tau bearing the HT7 (159PPGQK163) mid-region epitope.
Extracellularly applied oligomers of tau K18-WT (A), K18-V337M (B), and K18-N279K (C) oligomers internalized in hiPSC-derived neurons co-localized with
endogenous tau in the soma and the neurites. White arrowheads show sites of co-localization. Scale bar = 10 µm for all images. Figure extension in
Supplementary Figures S8A–C.
FIGURE 8 | Exogenous tau K18 oligomers internalized in the neurites of hiPSC-derived neurons co-localize with the nucleolar protein nucleolin. Panels (A–C) show
the co-localization of internalized oligomers of WT, V337M, and N279K tau K18, respectively, with nucleolin. Scale bar = 10 µm for all images. Figure extension in
Supplementary Figures S8D–F.
pitfall of thioflavin assays is that they appear to be probes
of protein conformation instead of aggregation status since
different folding behaviors can change the availability of different
proteinopathic proteins to the binding sites of the dye (Coelho-
Cerqueira et al., 2014; Wong et al., 2016; Hatami et al., 2017).
For this reason, the ability of thioflavin dyes to distinguish
between conformations of variants of the same protein can
sometimes be complicated (Hatami et al., 2017). Although
kinetics may remain apparently unaffected, our data using
TEM to characterize aggregates suggest that both mutations
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FIGURE 9 | Internalized tau K18 oligomers do not induce LDH-dependent cytotoxicity in SH-SY5Y cells. Increasing concentrations of oligomeric tau K18 variants
were applied to SH-SY5Y cells for 72 h, and the cells analyzed for LDH release. We found no significant difference in LDH release between the controls (buffer only
or maximum control) and the tau K18 variants at the concentrations studied (n = 3 each).
impact upon the aggregation of K18, a finding supported by
atomic force microscopy analysis (data not shown). Immuno-
reactivity data to probe conformation supported these findings.
These complementary findings in multiple assays build a strong
argument in support of the hypothesis that the mutations alter the
aggregation and conformation of tau K18. Interestingly, similar
profiles were observed for aggregation reactions carried out in
the absence of the heparin aggregation inducer. Moreover, the
FTD mutations altered the immuno-reactivity of aggregated K18-
WT. K18-V337M had lower reactivity to both tau antibodies
whilst the N279K mutation almost abolished reactivity to the
oligomer-preferring T22 antibody but its reactivity to A0024 was
comparable to that of K18-WT. Our results therefore, imply that
each mutation shifts protein conformation which in turn dictates
the pathway toward forming distinct aggregates. The consistent
observation that each protein variant had distinct aggregate
structures in several independent assays (both heparin-induced
and native-state aggregation) additionally supports mutation-
induced differences in protein aggregation and conformations,
similar to that previously described for amyloid beta (Hatami
et al., 2017). Two main reasons could account for the distinct
T22 reactivity even at 0 h, where the samples were monomeric.
Firstly, the T22 antibody is thought to selectively recognize an
oligomeric conformational epitope. However, the antibody can
also react with monomers which presumably share this same
epitope (Lasagna-Reeves et al., 2012b). Secondly, the differential
T22 binding to the tau K18 variants could also be due to the
introduced mutations since the exact epitope of the antibody
is unknown (it binds to the repeat domain region – amino
acids 244–372 of full length tau 441). It is conceivable that
the distinct aggregation and conformational dynamics of the
protein variants would also lead to notable differences in epitope
availability/recognition. Together, the data provided demonstrate
that the V337M and N279K disease-associated mutations induce
structural and conformational changes in tau K18 that are evident
at distinct stages of aggregation, including oligomers and fibrils.
Tau oligomers are a potential sensitive biomarker for
neurodegeneration (Sengupta et al., 2017) and can induce
endogenous tau aggregation upon cellular internalization
(Lasagna-Reeves et al., 2012a; Michel et al., 2014). Effects of
the disease mutations on the cellular uptake of structurally
characterized oligomers of tau K18 were therefore investigated.
Differences in oligomer uptake were observed in respect to tau
mutants. Irrespective of mutation, the uptake of K18 appeared
to be endocytic. Uptake of all K18 forms tested highlight
that different tau aggregates may each propagate disease
by spreading into non-diseased cells. However, differences
potentially mediated by aggregate conformation may provide
critical insights into shared and distinct molecular mechanisms
of tauopathies involving FTD and WT tau.
Consistent with previous reports that used recombinant or
brain isolates of tau (Frost et al., 2009; Guo and Lee, 2011;
Michel et al., 2014; Falcon et al., 2015; Ando et al., 2016;
Calafate et al., 2016), the K18-WT oligomers were most likely
internalized by endocytosis in both cell types, with same observed
for the FTD variants. Whilst all protein variants appeared to
be internalized by endocytosis, co-localized with endogenous
tau and were found both in the cytoplasm and nucleus, the
degree of internalization differed between the protein variants.
We speculative that the new aggregation and/or conformation
dynamics recorded in the presence of the FTD mutations may
change tau K18 interaction with cell surface proteins that regulate
endocytosis, resulting in altered cellular trafficking. In agreement,
binding to heparan sulfate proteoglycans regulates the cellular
internalization and inter-cellular propagation of aggregated tau,
and that blocking the activity or expression of heparan sulfate
proteoglycan prevents internalization (Holmes et al., 2013; Rauch
et al., 2018). However, it is unknown if WT and mutant tau
proteins bind heparan sulfate proteoglycans with the same
or different affinities. Furthermore, dysfunctions in key steps
in clathrin-mediated endocytosis have been implicated in tau
propagation and inclusion formation in AD, FTD and other
tauopathies (Ando et al., 2016; Calafate et al., 2016). It remains
to be studied if mutation-induced conformational changes do
modify tau internalization, propagation and toxicity in an in vivo
model. However, with the in vitro evidence presented in the
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current study, we can speculate that the altered conformations
of tau resulting from the FTD mutations leads to specific
changes in the protein’s vesicular uptake or receptor binding,
resulting in altered uptake efficiency. Another possibility is
that the FTD mutations alter the efficiency of degradation of
internalized tau K18 in each cell line, resulting in differential
amounts of internalized proteins. It is worth investigating if
oligomers of WT and mutated tau are degraded through the
same or different pathways, and if the mutations affect clearance
efficiency. Previous studies have shown that internalized WT
tau oligomers/aggregates and the internalized-endogenous tau
aggregate complexes they form intracellularly may be cleared by
autophagy (Wu et al., 2013; Usenovic et al., 2015). In agreement,
treating hiPSC-derived neurons with rapamycin reduces the
amount of internalized tau oligomers-endogenous tau aggregate
complexes, suggesting that lysosomal elimination is a common
degradation route for tau aggregates.
The ability of internalized exogenous tau aggregates to interact
with endogenous tau is critical for the efficient inter-cellular
propagation of tau aggregates and the associated neurotoxicity
(Lasagna-Reeves et al., 2012a; Michel et al., 2014; Wegmann
et al., 2015). The observed co-localization of all three protein
variants with endogenous tau suggests that internalized tau
K18 and the FTD variants can interact with endogenous tau,
indicating the potential for propagation by inducing endogenous
tau aggregation, possibly following a templated misfolding
mechanism as described previously for tau K18 (Guo and Lee,
2011; Michel et al., 2014). As both the FTD mutants and
WT K18 showed similar cellular distribution and localization,
it would suggest the potential for prion-like propagation of
the FTD mutant tau.
In hiPSC-derived neurons, the co-localization with nucleolin
suggests that internalized tau can be taken up into the nucleus,
and raises the possibility that internalized tau that gets into the
nucleus may have functions in protein biosynthesis. Nuclear
tau associates with nucleolin in AD brain, where reduced
nuclear tau levels correlated with decreased amounts of nucleolin
(Hernández-Ortega et al., 2016). Interaction of aggregated tau,
both WT and disease-associated mutated variants, with specific
ribosomal proteins can impair the protein synthesis machinery
(Meier et al., 2016). Given that pathological tau can impair
nucleocytoplasmic transport in AD brains and tau transgenic
mice (Eftekharzadeh et al., 2018), and the overexpression of the
N279K tau variant in a cell model is associated with increased
nuclear localization (Ritter et al., 2018), the effect of tau on the
protein synthesis machinery deserves further investigation.
Our findings that tau K18 oligomers, even at high
concentrations, did not significantly induce LDH release
was unexpected since some previous reports pointed to the
contrary (Lasagna-Reeves et al., 2010, 2012a). Nonetheless,
our present data is supported by other studies (Kumar et al.,
2014; Tepper et al., 2014; Kaniyappan et al., 2017). The origin
of these divergent data is unknown but could be explained by
differences in oligomer concentrations, preparation methods and
cytotoxicity assays. For example, 0.1–1 µM of full length tau-441
oligomers produced by seeding with oligomers from AD brain,
amyloid β or α-synuclein were toxic to cells, as measured by
the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4 sulfophenyl)-2H-tetrazolium (MTS) assay (Lasagna-Reeves
et al., 2010, 2012a). On the other hand, applying 10 µM
of tau K18 oligomers (recombinant or derived from Sf9
cells) to mouse primary cortical neurons or SH-SY5Y cells
did not result in significant cytotoxicity within 3–72 h, as
shown by the LDH or MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assays (Kumar et al., 2014; Tepper
et al., 2014). Whether or not exogenous tau oligomers induce
overt cytotoxicity, their most immediate toxic effect is likely to
be an impairment of the structural and functional integrity of
neurons and potentially other cell types. In support, internalized
tau oligomers impair neural transmission, cause dendritic spine
loss and increases in intracellular calcium levels and reactive
oxygen species without evidence of overt changes to cell viability
(Kumar et al., 2014; Tepper et al., 2014; Usenovic et al., 2015; Yin
et al., 2016; Kaniyappan et al., 2017).
Together, these results demonstrate that specific disease-
associated single nucleotide polymorphisms in tau can cause
drastic changes in protein conformation and aggregation. These
distinctive structural and conformational properties may be
crucial determinants of the inter-cellular transmission efficiency
of the oligomeric forms of these proteins. These findings may
provide a molecular explanation as to why tau extracts obtained
from different sources (including human tauopathy brains,
tau transgenic mice brains, and recombinant preparations)
have distinctive propagation potencies and endogenous tau
aggregation abilities in both cellular and animal preclinical
tauopathy models. Indeed, aggregated tau from transgenic
mice brains and recombinant sources have been shown to
have distinct conformations that can influence their seeding
capabilities (Falcon et al., 2015). It can be argued that critical
post-translational modifications such as phosphorylation and
the in vivo environment in which this process occurs might
have contributed to the conformational differences observed.
As the recombinant tau proteins used in the present study
were not phosphorylated, it can be said that phosphorylation
and sites of phosphorylation per se may not be responsible for
the conformational, structural and molecular activity differences
previously observed for tau aggregates from diverse sources. The
differential aggregation of the recombinant mutants reinforces
the conclusion that specific amino acid modifications are
sufficient to induce structural and functional differences in tau-
K18. Such structural and functional differences may then be
compounded by the differential phosphorylation of the mutant
forms of tau or their differential recruitment of endogenous tau.
Importantly, these findings may help to understand
why different tauopathies have distinct progression rates,
neuropathological features, inclusion formation and types of
inclusion (Delisle et al., 1999; Murrell et al., 1999; Sergeant et al.,
2005; Ghetti et al., 2015). Furthermore, these results may pave
the way for the development of more sensitive, disease- and
mutation-specific platforms for early, more accurate diagnosis of
tauopathies. Future studies should aim to ascertain if the findings
described here are applicable to tau isolates from tauopathy
brains: if their reported activity differences can be explained by
structural and conformational distinctions.
Frontiers in Cellular Neuroscience | www.frontiersin.org 13 July 2019 | Volume 13 | Article 296
fncel-13-00296 July 6, 2019 Time: 12:44 # 14
Karikari et al. Tau Mutations: Structural-Functional Effects
AUTHOR CONTRIBUTIONS
TK, DN, EH, and KM conceived and co-ordinated the study.
TK designed and conducted the experiments, analyzed the
data, and wrote the first draft of the manuscript. AG, CC-B,
and JC made significant contributions to hiPSC experiments,
immunocytochemistry, and confocal microscopy. DN, EH,
and KM contributed reagents and materials, made important
contributions to data interpretation, and critically revised the
initial manuscript draft. All authors discussed and commented
on the final manuscript.
FUNDING
The authors acknowledge support from the CRACK IT: Untangle
grant (NC/C013101/1) awarded by the National Centre for the
Replacement, Refinement and Reduction of Animals in Research.
TK was funded by a joint studentship from the University of
Warwick Chancellor’s Scholarship and the Biotechnology and
Biological Sciences Research Council (BBSRC) grant number
BB/J014532/1, through the Midlands Integrative Biosciences
Training Partnership. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation
of the manuscript.
ACKNOWLEDGMENTS
The authors wish to thank Prof. Alison Rodger and Dr. Nikola
Chmel of the Department of Chemistry, University of Warwick,
for useful discussions and use of analytical biophysics facilities.
The authors also thank Mr. Ian Hands-Portman (School of
Life Sciences, University of Warwick) for training TK and
providing him access to TEM facilities. TK acknowledges Drs.
Mussa Quareshy and Greg Walkowiak for assistance with protein
purification and microplate reader access, respectively. The
authors acknowledge support from the Research Councils UK
Block Grant at the University of Warwick for the payment of
open access fee.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fncel.
2019.00296/full#supplementary-material
FIGURE S1 | The FTD mutations cause structural changes in the properties of tau
K18 filaments. (A) Representative TEM images of K18-WT, showing PHFs and
SFs. (B) Representative electron micrographs of K18-V337M, which formed
amorphous aggregates [examples shown in (i), (ii), and (iii)] and short filaments [(iv)
and (v)]. (C) Representative electron micrographs of K18-N279K, showing bundled
filaments of varying shapes and widths. Scale bar = 100 nm for all images.
n = 3 independent experiments for each protein. This figure is an extension
of Figure 2.
FIGURE S2 | Uncropped dot blot data used for immuno-reactivity analysis in
Figure 4. (A) Dot blot intensity data for K18-WT, K18-V337M, and K18-N279K
following total tau A0024 reactivity. (B) T22 antibody reactivity profiles of K18-WT,
K18-V337M, and K18-N279K. For better visualization, the sites of dot blotting are
highlighted with black circles.
FIGURE S3 | Dominant aggregate conformers of the tau K18 variants are
unaffected by seeded aggregation. Endpoint aggregates of K18 WT, V337M, and
N279K from 4 days reactions were used to seed the aggregation of each protein
in turn. The resulting product, after a further 4 days of incubation at room
temperature, were analyzed by TEM imaging (A, unseeded; B, seeded with WT;
C, seeded with V337M seeded; and D, seeded with N279K). Scale
bars = 100 nm for all images.
FIGURE S4 | Structural characterization of fluorescently labeled oligomers of tau
K18 and its FTD variants. (A–C) Representative TEM characterization of tau K18
oligomers labeled with Alexa Fluor 488 conjugated maleimide demonstrating the
presence of granular structures for K18-WT, K18-V337M, and K18-N279K,
respectively. Insets refer to higher magnification images. Scale bars for all
images = 200 nm and 20 nm for insets. (D) Non-denaturing SDS PAGE image of
labeled tau K18 oligomers.
FIGURE S5 | Uptake of extracellularly applied tau K18 oligomers into SH-SY5Y
cells. Seeded cells were supplied with 10 µM tau K18 oligomers and incubated
for 24 h at 37◦C, 5% CO2, following which the spent media were removed and
the cells washed with warm 10 mM PBS before new tau-free media was added.
Uptake of oligomers was demonstrated using confocal microscopy. Panels (A–C)
show cellular internalization of K18-WT, K18-V337M, and K18-N279K oligomers,
respectively. Scale bar = 10 µm for all images.
FIGURE S6 | Internalized oligomers of the tau K18 variants localize to the nuclei
and cytoplasm of SH-SY5Y cells. Oligomeric aggregates of tau K18-WT (A),
K18-V337M (B), and K18-N279K (C) internalized by the SH-SY5Y cells appeared
to be distributed in the cytoplasm (open arrow heads) and nucleus (filled arrow
heads). Scale bars = 10 µm for all images.
FIGURE S7 | Higher resolution images of internalized tau K18 oligomers in
SH-SY5Y cells. The images here show AF-maleimide-labeled tau K18 oligomers
(green) taken up mainly into the cytoplasm of K18-WT, K18-V337M, and
K18-N279K (A–C, respectively). Scale bar = 10 µm for all images.
FIGURE S8 | Colocalization of tau K18 with endogenous tau and nucleolin at high
intensity. These figures show digitally increased intensity of selected regions from
the images in Figures 7, 8 to better demonstrate colocalization of tau K18 WT,
V337M, and N279K with endogenous tau (A–C, respectively) or nucleolin (D–F,
respectively). For better composite color appreciation, colocalization is shown in
yellow - merger of red (endogenous tau or nucleolin) and green (tau K18) channels
or white – merger of magenta (endogenous tau or nucleolin) and green (tau K18)
channels. Arrows point to regions of colocalization.
FIGURE S9 | Incubation in cold conditions blocks the internalization of tau K18
oligomers by SH-SY5Y cells. (A–C) Oligomer uptake was significantly reduced for
tau K18-WT, K18-V337M, and K18-N279K, respectively when SH-SY5Y cells
were incubated at 4◦C instead of 37◦C (as shown in Figure 6).
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